Form PTO-1449		•	ent of Commerce	Attorney Docket N	lo.	Sen	at No		
(Rev. 8-88)			Patent and Tr	ademark Office	C-3169/1/US		1 00/4	51,641	
INFORMATION DISCLOSURE STATEMENT					Applicant	× ×		~	
(Use soverall species if necessary)					Gao, D. et al.	120	4 -	W/V	
		1		Filing Date	*CX		NO NO SHAPE	>	
	MAY 6 2 2002						W/ Grou	ib No .	
		P. C.			November 30, 19	99 	(%), 161!	<u> </u>	
		THADEMP	· ·	J.S. PATENT DOCU	IMENTS		Group 1619	<i>On</i>	
Examiner	ļ	Patent						Filing	Date
Initial*	-	Number	Issue Date	Name		Class	Subclass		opriate
3,	AC	5,869,096	Feb 9, 1999	Barclay et al		424	468	Dec 9.	1994
	AD	5,756,529	May 26, 1998	Isakson et al		514	406	ļ	
	AE	5.633,272	May 27, 1997	Talley et al.		514	378		
	AF	5,474,784	Dec 12, 1995	Stevens et al.		424	456	1	
	AG	5,342,624	Aug 30, 1994	McNeill et al.		424	451		
	AH	4,866.848	Sep 12, 1989	Conte et al.		424	466		
2.5	AI	4,681,755	Jul 21, 1987	Colombo et al	 	424	486	<u> </u>	
FOREIGN PATENT DOCUMENTS									
Examiner		Document						Trans	slation
Initial*	ļ	Number	Date	Country		Class	Subclass	Yes	No
4. 15	BC	WO 97/44028	Nov 27, 1997	MALO 10 1		A61K	31/365		X
4.5	BD	WO 99/09988	Mar 4, 1999	WIPO 141		A61K	31/54		X
		OTHE	R DOCUMENTS	(Including author, tit	le, date, pertinent pa	ages, etc.	.)		
	CD	Abdou (1989). [Dissolution, Bioay	vailability and Bioequ	uivalence, pp. 58-66,	457-458	3. Mack Pub	ishing C	0.
· · · · ·	CE	American Pharm	naceutical Associ	ation (1986). Handl	book of Pharmaceuti	cal Excip	ients, pp. 1-2	2, 5, 9-11	. 26-
'4 '		33, 39-40, 45	5-48, 53-58, 93-9	8, 113-115, 119 - 121	, 123-126, 128-129,	134-135,	138-140, 15	3-162, 16	66-169,
	ļ	177-183, 209)-211, 214-215, 2	34-239, 261-262, 26	66-268, 271-272 <u>,</u> 275	5-278, 28	4-293. 298-3	00, 304-	308
	CF				aded "Pharmacokine				
	CG				inetik (In Turkish; be				
	<u> </u>				'), pp. 35-36. No En				
	СН	i			tion. In Lieberman e	et al. (ed.) Pharmaceu	itical Dos	age
				1, pp. 131-193. Mar					
	CI			ets. In Lachman et	al. (ed.) The Theory	and Prac	tice of Indus	trial Phai	macy,
		pp. 293-373. Lea & Febiger.							
-	CJ		•		esting. Chap. 77 in	Remingto	on's Pharmac	ceutical	
		Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co.							
	СК	Geçgil (1991). Farmasötik Teknolojiye Baslangiç (in Turkish; believed to translate as "Introduction to							
		Pharmaceutical Technology"), pp. 346-348. No English translation available. Güven (1979). Ilaç Endüstrisi Teknolojisi (in Turkish; believed to translate as "Drug Industry Technology"), pp.							
	CL				believed to translate	as "Drug	g Industry Te	chnology	/"). pp.
			nglish translation						
,	СМ				of celecoxib in oste			College c	of
	21				an Diego, California				
	CN				k Teknoloji (In Turkis 1, pp. 367-382. No l				eneral
, .	CO Igzü (1983). Genel Endüstriyel Farmasötik Teknoloji II (In Turkish; believed to translate as "General ar						and		
. *		Industrial Pha	armaceutical Tec		1-241. No English t	ranslatio	n available.		
Examiner				Date Considered	01.				
	\$ 7.02								
*Examiner:					nce with MPEP §609; dinext communication to		nrough citation	if not in	
conformance and not considered. Include copy of this form with next communication to applicant.									

Form PT			Attorney Docket No.	Serial No.					
(Rev. 8-8	3)	Patent and Trademark Office	C-3169/1/US	09/451,641					
	-	ORMATION DISCLOSURE STATEMENT	Applicant	-,					
/	~	(Ose several sheets if necessary)	Gao, D. et al.						
	sá A V	6 2 2002 (%)	Filing Date	Group No					
PA	,		November 30, 1999	1615					
	Richard Richard	OTHER DOCUMENTS (Including author, tit	le, date, perfinent pages, etc	.)					
	СР	Karım et al. (1997). SC-58635 (celecoxib): a highly s	elective inhibitor of cyclooxy	genase-2. Disposition					
,		kinetics in man and identification of its major CYP-Research 14, p. S-617, Abstr. 3469.	450 isozyme in its biotransfo	rmation. Pharmaceutical					
	CQ	Kayaalp (date unknown). Tibbi Farmakoloji (ln Turkis	h: believed to translate as "N	Medicinal Pharmacology")					
		Vol. 1, pp. 27-28 and Vol. 2, p. 1050. No English	translation available.	in the state of th					
) - 7	CR	Lane (1997). Pain management in osteoarthritis: the		urnal of Rheumatology 24					
- 1		(Supp 49), 20-24.							
+	CS	Parnham (1996). Inflammation: mechanisms and the	rapeutics. Drug News & Per	spectives 9, 631-639.					
	СТ	Peck <i>et al.</i> (1989). Tablet formulation and design. In Tablets, 2nd ed., Vol. 1, pp. 75-130. Marcel Dekke		naceutical Dosage Forms					
†	cu	Proudfoot (1990). Factors influencing bioavailability:		urntion from the					
		gastrointestinal tract. In Aulton (ed.) Pharmaceutic							
	cv	Rubinstein (1990). Tablets. In Aulton (ed.) Pharmace							
		321.		, - · · · · · · · · · · · · · · · · · ·					
	cw	Shangraw (1989) Compressed tablets by direct com	pression. In Lieberman et al	. (ed.) Pharmaceutical					
		Dosage Forms: Tablets, 2nd ed., Vol. 1, pp. 195-246. Marcel Dekker.							
1	СХ	Wadke et al. (1989). Preformulation testing. In Liebe		tical Dosage Forms					
****	Tablets, 2nd ed., Vol. 1, pp. 1-73. Marcel Dekker. See pp. 5, 47-48.								
	CY	Welling et al. (1991) Pharmaceutical Bioequivalence	<u>, pp. 413-414 Marcel Dekke</u>	er.					
Examiner		Date Considered	/ /						
		3	6/2002						
* Examiner:	Initia	al if citation considered, whether or not citation is in conforman	ice with MPEP §609; draw line th	rough citation if not in					
	conf	ormance and not considered. Include copy of this form with n	ext communication to applicant.						



Form PTO)	•	ent of Commerce	Attorney Docket N	O	Ser	iai No		i
(Rev. 8-88)		Patent and T	rademark Office						
					C-3169/1/US		09/	451,641		
	•	DRMATION DISC			Applicant					1
1		Use several sh	eets if necessar	()	Coo D at al					
1					Gao, D. et al.	-)-				
MAY 0	2 200	19 ST			Filing Date		Gro	oup No		
12		· ω;			November 30, 199	99	161	5		
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		T							•	
RAD	EMA		l	J.S. PATENT DOCU	JMENTS					
Examiner		Patent			· · · · · · · · · · · · · · · · · · ·	T		Filing	Doto	_
Initial*		Number	Issue Date	Name		Class	Subclass	_	opriate	
	AJ	6.040,850	Apr 11, 2000	Young et al.		514	183	Jul 7		\dashv
1	AK	5,932,576	Aug 3, 1999	Anantanarayan et	al	514	235.5		2, 1998	-
	AL	5.739.166	Apr 14, 1998	Reitz et al		514	602	IVIdy Z.	<u>4. 1990</u>	
-05	АМ	5.643,933	Jul 1, 1997	Talley et al.		514	372	-	- / / /	\exists
- - 	AN	5,540,669	Jul 30, 1996	Sage et al.		604	290			-
	AO	5,474,995	Dec 12, 1995	Ducharme et al.		514	241	*	<i>\$</i> _{1,2,1}	\dashv \Diamond
	AP	4.865,849	Sep 12, 1989	Conte et al		424	466	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	· **.	-
			30p 12, 1300	Outro of the		424	400	1/2		,
			FOI	REIGN PATENT DO	CUMENTS			\V _/	(5) (5)	
Examiner		Document	.						slation /	£22
Init al*	D.F.	Number	Date	Country		Class	Subclass	Yes	No	100
	BE	WO 95/00501	Jan 5, 1995	WIPS wi		C07D	277/02		X	1
	BF	WO 95/15316	Jun 08, 1995	WIPO 101		C07D	231/12	_	X	-
_	BG	WO 95/18799	Jul 13, 1995	WIPO :C C		C07D	307/58		X	╛
	CZ				tle, date, pertinent pa					
	DA				rmacotherapy 17(2).					4
	DA				ches Worterbach (in					
ļ			slation provided.	, our Edition, waiter	de Gruyter, Berlin, I	New York	t, pp. 278, 8	54, 954, 1	1109.	İ
	DB			phihitore: basic soio	nce and clinical impl	iostians	A	100/5	.D.	_
		1S-2S.	OOX-2 Specific II	mibitors. Dasic scie	nce and clinical impr	ications.	Amer. J. IV	ea. 106(5	в), pp.	
	DC		Gastrointestinal	effects of nonsteroid	dal anti-inflammatory	activity.	Amer. J.Me	ed. 106(5I	В), рр.	
	DD			formulation. In Ren	nington's Pharmacy,	19th edi	tion, Vol. II,	Chap 83	. Mack	1
<u> </u>	חב		Group, p. 1449.							-
ż	DE				na In Goodman & (3ilman's	Pharmacolo	igical Bas	is of	
-	DF			iap. 28 McGraw-Hi						4
	וטי	"Pharmacou	namnazeutische	for the Classes	dium und Beruf (in G	erman, b	elleved to t	anslate a	ıs	
		Moshy Gmb	nicar recnnology h & Co KC Bori	nor the Classroom a	and Professional App	nications), /th editic	n Ulsteii	n	
	DG				10-212, 231-238. Er					-
Ψ.	50	implications	Amer J Med 1	or nonsteroidal anti- _06(5B), pp. 13S-24:	inflammatory drugs:	pnysiolo	gic foundati	ons and c	linical	
Examiner	1	пприсавонз.	7 arici. J. Wed.	Date Considered	J			 _		4
		-		Pare Considered	11-0/00					
		A		1	A CONTRACTOR OF THE PARTY					1

* Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Initial	641
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) U.S. PATENT DOCUMENTS Examiner Patent Number Issue Date Name Class Subclass If	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) Gao, D. et al. Filing Date November 30, 1999 1615 U.S. PATENT DOCUMENTS Examiner Initial* Patent Number Issue Date Name Class Subclass If	NU7
(Use several sheets if necessary) Gao, D. et al. Filing Date November 30, 1999 1615 U.S. PATENT DOCUMENTS xaminer Patent Number Issue Date Name Class Subclass If	N.7
Filing Date November 30, 1999 1615 U.S. PATENT DOCUMENTS Examiner Patent Number Issue Date Name Class Subclass If	NO :
U.S. PATENT DOCUMENTS Xaminer	
U.S. PATENT DOCUMENTS Examiner Patent Number Issue Date Name Class Subclass If	
xaminer Patent Number Issue Date Name Class Subclass If	
xaminer Patent Number Issue Date Name Class Subclass If	
nitial* Number Issue Date Name Class Subclass If	-iling Date
ilida 11.dinos.	f Appropria
	Dec 9, 1994
AD 5,756,529 May 26, 1998 Isakson <i>et al.</i> 514 406	
AE 5,633,272 May 27, 1997 Talley et al. 514 378	
AF 5,474,784 Dec 12, 1995 Stevens et al. 424 456	
AG 5,342.624 Aug 30, 1994 McNeill et al. 424 451	
AH 4.866,848 Sep 12, 1989 Conte et al. 424 466	
Al 4,681,755 Jul 21, 1987 Colombo et al. 424 486	
FOREIGN PATENT DOCUMENTS	
xaminer Document	Translatio
Class Subclass	Yes N
Initial Number Sale Acad Acad Acad Acad Acad Acad Acad Acad	>
BC WO 97/44028 Nov 27, 1997 WPO A6 TK 31/365 BD WO 99/09988 Mar 4, 1999 WPO A61K 31/54	>
CD Abdou (1989). Dissolution, Bioavailability and Bioequivalence, pp. 58-56, 457-456. Mack Publish	ing Co.
CF American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5	5, 9-11, 26-
CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129,134-135, 138-140, 153-162,	5, 9-11, 26- 166-169.
CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115. 119-121, 123-126. 128-129,134-135, 138-140. 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713.	5, 9-11, 26- 166-169.
 CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129,134-135, 138-140, 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available 	5, 9-11, 26- 166-169.), 304-308.
CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129,134-135, 138-140, 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutic	5, 9-11, 26- 166-169.), 304-308.
CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129,134-135, 138-140, 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker.	5, 9-11, 26- 166-169. 0, 304-308. le cal Dosage
CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129,134-135, 138-140, 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industria	5, 9-11, 26- 166-169. 0, 304-308. le cal Dosage
 CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115. 119-121, 123-126. 128-129,134-135, 138-140. 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman <i>et al.</i> (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. In Lachman <i>et al.</i> (ed.) The Theory and Practice of Industrial pp. 293-373. Lea & Febiger. 	5, 9-11, 26- 166-169.), 304-308. le. cal Dosage
 CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115. 119-121, 123-126. 128-129,134-135, 138-140. 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman <i>et al.</i> (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. In Lachman <i>et al.</i> (ed.) The Theory and Practice of Industrial pp. 293-373. Lea & Febiger. CJ DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutics 	5, 9-11, 26- 166-169.), 304-308. le. cal Dosage
 CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115. 119-121, 123-126. 128-129,134-135, 138-140. 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman <i>et al.</i> (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. In Lachman <i>et al.</i> (ed.) The Theory and Practice of Industrial pp. 293-373. Lea & Febiger. CJ DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutic Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co. 	5, 9-11, 26- 166-169.), 304-308. le. cal Dosage al Pharmac
 CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115. 119-121, 123-126. 128-129,134-135, 138-140. 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industria pp. 293-373. Lea & Febiger. CJ DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutical Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co. CK Geçgil (1991). Farmasotik Teknolojiye Baslangiç (in Turkish, believed to translate as "Introduction" 	5, 9-11, 26- 166-169.), 304-308. le. cal Dosage al Pharmac
 CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115. 119-121, 123-126. 128-129,134-135, 138-140. 153-162, 177-183, 209-211. 214-215, 234-239, 261-262. 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available. CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industria pp. 293-373. Lea & Febiger. CJ DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutics. 17th ed., pp. 1424-1431. Mack Publishing Co. CK Geçgil (1991). Farmasotik Teknolojiye Baslangiç (in Turkish, believed to translate as "Introduction Pharmaceutical Technology"), pp. 346-348. No English translation available. 	5, 9-11, 26- 166-169.), 304-308. le. cal Dosage al Pharmac utical
 CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115. 119-121, 123-126, 128-129,134-135, 138-140. 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300. CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available. CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industrial pp. 293-373. Lea & Febiger. CJ DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutics. 17th ed., pp. 1424-1431. Mack Publishing Co. CK Geçgil (1991). Farmasotik Teknolojiye Baslangiç (in Turkish, believed to translate as "Introduction Pharmaceutical Technology"), pp. 346-348. No English translation available. CL Güven (1979). Ilaç Endustrisi Teknolojisi (in Turkish; believed to translate as "Drug Industry Technology"). Pp. 346-348. No English translation available. 	5, 9-11, 26- 166-169.), 304-308. le cal Dosage al Pharmac utical
CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129,134-135, 138-140, 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish; believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industria pp. 293-373. Lea & Febiger. CJ DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutics Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co. CK Geçgil (1991). Farmasötik Teknolojiye Baslangiç (in Turkish, believed to translate as "Introduction Pharmaceutical Technology"), pp. 346-348. No English translation available. CL Güven (1979). Ilaç Endustrisi Teknolojisi (in Turkish; believed to translate as "Drug Industry Tech 67-81. No English translation available. CM Hubbard et al. (1998). Efficacy, tolerability and safety of celecoxib in osteoarthritis. American Co	5, 9-11, 26- 166-169.), 304-308. le cal Dosage al Pharmac utical
CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129,134-135, 138-140, 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasótik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available. CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industrial pp. 293-373. Lea & Febiger. CJ DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutics Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co. CK Geçgil (1991). Farmasotik Teknolojiye Baslangiç (in Turkish, believed to translate as "Introduction Pharmaceutical Technology"), pp. 346-348. No English translation available. CL Güven (1979). Ilaç Endustrisi Teknolojisi (in Turkish; believed to translate as "Drug Industry Technology"). Pp. 346-348. No English translation available. CM Hubbard et al. (1998). Efficacy, tolerability and safety of celecoxib in osteoarthritis. American Co-Rheumatology 62nd National Scientific Meeting, San Diego, California, November 1998.	5, 9-11, 26- 166-169.), 304-308. le. cal Dosage al Pharmac utical in to
 CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129,134-135, 138-140, 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available. CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industria pp. 293-373. Lea & Febiger. CJ DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutics Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co. CK Geçgil (1991). Farmasotik Teknolojiye Basiangiç (in Turkish, believed to translate as "Introduction Pharmaceutical Technology"), pp. 346-348. No English translation available. CL Güven (1979). Ilaç Endustrisi Teknolojisi (in Turkish; believed to translate as "Drug Industry Tech 67-81. No English translation available. CM Hubbard et al. (1998). Efficacy, tolerability and safety of celecoxib in osteoarthritis. American Co Rheumatology 62nd National Scientific Meeting, San Diego, California, November 1998. CN Igzü (date unknown). Genel ve Endüstriyel Farmasötik Teknoloji (In Turkish; believed to translate 	te. al Dosage al Pharmac utical utical un to bliege of as "Gener
 CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115. 119-121, 123-126. 128-129,134-135, 138-140. 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available. CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutic Forms. Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industria pp. 293-373. Lea & Febiger. CJ DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutics. Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co. CK Geçgil (1991). Farmasötik Teknolojiye Baslangiç (in Turkish, believed to translate as "Introduction Pharmaceutical Technology"), pp. 346-348. No English translation available. CL Güven (1979). Ilaç Endustrisi Teknolojisi (in Turkish; believed to translate as "Drug Industry Technology"). Pp. 346-348. No English translation available. CM Hubbard et al. (1998). Efficacy, tolerability and safety of celecoxib in osteoarthritis. American Congressional Religional Scientific Meeting, San Diego, California, November 1998. CN Igzü (date unknown). Genel ve Endüstriyel Farmasötik Teknoloji (In Turkish; believed to translate and Industrial Pharmaceutical Technology"). Vol. 1, pp. 367-382. No English translation availation availation available. 	ie al Pharmac utical utical utical utical an to be as "Gener lable.
 CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129,134-135, 138-140, 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available. CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. in Lachman et al. (ed.) The Theory and Practice of Industrial pp. 293-373. Lea & Febiger. CJ DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutics Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co. CK Geçgil (1991). Farmasotik Teknolojiye Baslangiç (in Turkish, believed to translate as "Introduction Pharmaceutical Technology"), pp. 346-348. No English translation available. CL Güven (1979). Ilaç Endustrisi Teknolojisi (in Turkish; believed to translate as "Drug Industry Tech 67-81. No English translation available. CM Hubbard et al. (1998). Efficacy, tolerability and safety of celecoxib in osteoarthritis. American Co Rheumatology 62nd National Scientific Meeting, San Diego, California, November 1998. CN Igzü (date unknown). Genel ve Endustriyel Farmasotik Teknoloji (In Turkish; believed to translate and Industrial Pharmaceutical Technology"). Vol. 1, pp. 367-382. No English translation available. CO Igzü (1983). Genel – Endüstriyel Farmasotik Teknoloji – II (In Turkish, believed to translate as "Gound trans	ie al Pharmac utical utical utical utical an to be as "Gener lable.
 CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115. 119-121, 123-126, 128-129,134-135, 138-140, 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available. CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. in Lachman et al. (ed.) The Theory and Practice of Industrial pp. 293-373. Lea & Febiger. CJ DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutics Sciences. 17th ed., pp. 1424-1431. Mack Publishing Co. CK Geçgil (1991). Farmasotik Teknolojiye Baslangic (in Turkish; believed to translate as "Introduction Pharmaceutical Technology"), pp. 346-348. No English translation available. CL Given (1979). Ilaç Endustrisi Teknolojis (in Turkish; believed to translate as "Drug Industry Tech 67-81. No English translation available. CM Hubbard et al. (1998). Efficacy, tolerability and safety of celecoxib in osteoarthritis. American Co Rheumatology 62nd National Scientific Meeting, San Diego, California, November 1998. CN Igzü (date unknown). Genel ve Endüstriyel Farmasötik Teknoloji (In Turkish; believed to translate and Industrial Pharmaceutical Technology"). Vol. 1, pp. 367-382. No English translation available. Industrial Pharmaceutical Technology – II"), pp. 211-241. No English translation available. 	ie al Pharmac utical utical utical utical an to be as "Gener lable.
 CE American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129,134-135, 138-140, 153-162, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300 CF Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. CG Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish: believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available. CH Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutic Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. CI Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industrial pp. 293-373. Lea & Febiger. CJ DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutical Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co. CK Geçgil (1991). Farmasotik Teknolojiye Baslangiç (in Turkish, believed to translate as "Introduction Pharmaceutical Technology"), pp. 346-348. No English translation available. CL Güven (1979). Ilaç Endustrisi Teknolojisi (in Turkish; believed to translate as "Drug Industry Technology"). Pp. 346-348. No English translation available. CM Hubbard et al. (1998). Efficacy, tolerability and safety of celecoxib in osteoarthritis. American Co-Rheumatology 62nd National Scientific Meeting, San Diego, California, November 1998. CN Igzü (date unknown). Genel ve Endüstriyel Farmasötik Teknoloji (In Turkish; believed to translate and Industrial Pharmaceutical Technology"). Vol. 1, pp. 367-382. No English translation avail and Industrial Pharmaceutical Technology"). Vol. 1, pp. 367-382. No English translation avail and Industrial Pharmaceutical Technology"). Vol. 1, pp. 367-382. No English translation avail. 	ie al Pharmac utical utical utical utical an to be as "Gener lable.

Form PTO-144 (Rev. 8-88)	9.S. Department of Commerce Patent and Trademark Office	Attorney Docket No C-3169/1/US	Serial No 777 09/451,641	
INF	FORMATION DISCLOSURE STATEMENT	Applicant		
	(Use several sheets if necessary)	Gao, D. et al.		
		Filing Date	Group No	
		November 30, 1999	1615	
	OTHER DOCUMENTS (Including author, ti	tle, date, pertinent pages, etc.)		
, ₁ CP	Karim et al. (1997). SC-58635 (celecoxib); a highly s kinetics in man and identification of its major CYP Research 14, p. S-617, Abstr. 3469	elective inhibitor of cyclooxyger 450 isozyme in its biotransforma	nase-2 Disposition ation Pharmaceutical	
co		sh; believed to translate as "Med translation available.	dicinal Pharmacology"),	
_ ;			nal of Rheumatology 24	
CS CT	1 1 2	Lieberman et al. (ed.) Pharmad	ectives 9, 631-639. ceutical Dosage Forms	
cu		factors influencing drug absorpt		
CV		eutics, The Science of Dosage	Form Design, pp. 304-321.	
CW	 Shangraw (1989). Compressed tablets by direct composage Forms: Tablets, 2nd ed., Vol. 1, pp. 195-2 	ipression. In Lieberman <i>et al.</i> (6 246. Marcel Dekker.	ed.) Pharmaceutical	
СХ	Wadke et al. (1989). Preformulation testing. In Liebe 2nd ed., Vol. 1, pp. 1-73. Marcel Dekker. See pp	erman <i>et al.</i> (ed.) Pharmaceutica	al Dosage Forms: Tablets.	
CY		e, pp. 413-414. Marcel Dekker.		
xaminer	Date Considered	. 1/23/12		
Examiner Init	tial if citation considered, whether or not citation is in conformal informance and not considered. Include copy of this form with r	nce with MPEP §609 draw line thro	ough citation if not in	